Royal Drugs

What Royal Drugs does

Royal Drugs, founded in 1934 and headquartered in Ottawa, is a Canadian specialty pharmacy operator that provides integrated specialty pharmacy, infusion compounding, retail pharmacy, and total parenteral nutrition (TPN) services. The company is a wholly-owned subsidiary of Capital Health Partners Inc, which also owns sister company Ontario Medical Supply. Royal Drugs operates nine licensed pharmacies across five provinces (Ontario, Manitoba, Saskatchewan, Alberta, and British Columbia), including four compounding facilities acquired from Calea Canada in August 2025 and rebranded under Royal Drugs effective November 14, 2025. The company also runs six stand-alone infusion and injection clinics in Ajax, Belleville, Cornwall, Mississauga, Port Hope, and Smiths Falls, and operates retail pharmacy counters inside The Ottawa Hospital General and Civic campuses. Core technical capabilities include USP <797>-compliant sterile compounding cleanrooms, cold chain logistics for temperature-sensitive biologics, and an electronic health record integration layer supporting coordination with Ontario Health atHome.

The business model is a multi-channel pharmacy services platform monetized primarily through quote-based enterprise contracts with healthcare providers, government home-care coordinators, and hospitals, layered with retail transaction revenue at hospital-based counters. Specialty pharmacy revenue (customized medication programs, co-pay management, reimbursement navigation, complimentary delivery) operates on a recurring managed-services basis; infusion compounding and TPN revenue is captured through per-patient compounding fees plus equipment rental (infusion pumps and poles); and retail pharmacy revenue is a transaction-based stream covered by provincial drug plans (OHIP, AB Health, BC MSP) plus out-of-pocket payments. Pricing is not publicly disclosed and is structured as multi-year contracts for enterprise services and pay-as-you-go for retail. Customers span healthcare providers and physician practices (primary segment), patients requiring infusion or specialty medications, hospital inpatients and outpatients, and patients with advanced nutritional needs. Named enterprise customers include Ontario Health atHome and The Ottawa Hospital, supported by a sales motion built on dedicated account management teams and direct B2B partnerships with clinics and prescribing physicians.

Name

Royal Drugs

Legal name

Royal Drugs Inc

Website

https://royaldrugs.ca

Company type

Private

Founded year

1934

Operating status

Operating

Short description

Royal Drugs, founded in 1934 and owned by Capital Health Partners Inc, operates nine pharmacies across five Canadian provinces delivering specialty pharmacy, infusion compounding, retail pharmacy, and total parenteral nutrition services to healthcare providers, hospital patients, and home infusion clients.

Ownership category

akta.pro rank

Product category

Specialty Pharmacy Services

NAICS

Pharmacies and Drug Retailers (45611), Ambulatory Health Care Services (621)

SIC

Services-Health Services (8000), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Infusion & Home Infusion Pharmacy Services (HLAFALAG)

akta.pro secondary industries

Home Infusion Therapy & IV Nursing Services (HLADAFAG), Medication Therapy Management (MTM) & Clinical Pharmacy Services (HLAFALAH), Mail-Order & Home Delivery Pharmacies (HLAFALAD)

Keywords

• Specialty pharmacy services
• Infusion compounding
• Total parenteral nutrition
• Retail pharmacy services
• Sterile pharmaceutical compounding

Headquarters

HQ city

Ottawa

HQ country

Canada

HQ region

North America

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Specialty Pharmacy Services: Revenue generated from customized specialty medication programs including co-pay management, reimbursement navigation, and medication delivery. Services streamline care for physicians and patients with support for various therapeutic areas including ophthalmology, dermatology, immunology, gastroenterology, rheumatology, neurology, and oncology.
2. Infusion Compounding Services: Revenue from preparation and dispensing of injectable and infusion therapies, total parenteral nutrition (TPN), and related supplies. Services include rental of infusion pumps and poles, medical supplies, and equipment supporting infusion therapy administration.
3. Retail Pharmacy Services: Traditional prescription dispensing services at retail pharmacy locations within hospital settings (The Ottawa Hospital General and Civic campuses). Includes free home delivery, pharmacist counselling, and minor ailment prescribing.
4. Total Parenteral Nutrition (TPN): Comprehensive home TPN services including custom-compounded formulations, ambulatory infusion pumps, supply management, and ongoing clinical support for patients with advanced nutritional needs.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Royal Drugs provides specialty pharmacy programs, infusion compounding, retail pharmacy, and total parenteral nutrition (TPN) services through licensed, IV therapy-accredited pharmacies in Ontario, Alberta, and British Columbia. Services include customized specialty medication programs with co-pay management and patient counselling, sterile IV therapy preparation in USP <797>-compliant cleanroom environments, hospital-based retail pharmacy operations, and home TPN delivery with ambulatory infusion pumps.

Product overview

Royal Drugs operates as a unified pharmacy services company offering four integrated core services: Specialty Pharmacy (customized medication programs with clinical support and reimbursement assistance), Infusion Compounding (sterile IV therapy preparation in accredited cleanroom facilities), Retail Pharmacy (hospital-based prescription services with minor ailment prescribing), and Total Parenteral Nutrition (TPN for patients with advanced nutritional needs). The company operates nine pharmacies across Canada, formerly including Calea locations now unified under the Royal Drugs brand following acquisition by Capital Health Partners in August 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Specialty Pharmacy Customized specialty medication programs that streamline care for physicians and patients, offering end-to-end clinic support, co-pay management, patient reminder calls, medication counselling, complimentary medication delivery, and cold chain expertise for complex medications across ophthalmology, dermatology, immunology, gastroenterology, rheumatology, neurology, and oncology.
• Infusion Compounding IV therapy-accredited pharmacy services providing preparation of injectable and infusion therapies in USP <797>-compliant sterile cleanroom environments, total parenteral nutrition dispensing, flexible medication delivery to clinic or patient's preferred location, and infusion pump and pole rentals.
• Retail Pharmacy Community-focused prescription services located within The Ottawa Hospital on both General and Civic campuses, offering free home delivery, pharmacist counselling, injection administration, minor ailment prescribing, and over-the-counter products for hospital inpatients, outpatients, and local patients.
• Total Parenteral Nutrition (TPN) Life-sustaining therapy delivering complete nutrition intravenously for patients unable to eat or absorb nutrients through their digestive systems, featuring custom-compounded formulations, ambulatory infusion pumps, complete supply management, and ongoing clinical monitoring and adjustment for home administration.

Quantifiable outcome

• Streamlined specialty medication management reducing administrative burden for physician practices
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Ontario Health atHomecoreStrategic or Co-development Partner · 14 November 2025Royal Drugs services Ontario Health atHome by providing infusion therapy to their clients. This partnership was established following the acquisition of Calea (Canada) by Capital Health Partners. Royal Drugs provides comprehensive home infusion services as part of this healthcare coordination relationship.
• Ontario Medical SupplycoreStrategic or Co-development Partner · 1 August 2025Ontario Medical Supply is a sister company under parent company Capital Health Partners Inc. Royal Drugs partners with Ontario Medical Supply to service Ontario Health atHome and other healthcare organizations across Canada with infusion therapy services. Both companies operate as subsidiaries of Capital Health Partners.
• Fresenius KabiminorOthers · 1 August 2025Fresenius Kabi sold its Canadian Calea business to Capital Health Partners Inc in August 2025. The acquisition brought four Calea pharmacy locations (Mississauga, Hamilton, Calgary, Burnaby) into the Royal Drugs network, expanding Royal Drugs' presence across Canada.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/royaldrugs

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Royal Drugs